Bid BH3-R8 – 0.5 mg

Overview

Bid BH3-R8 is a powerful peptide designed for research focused on apoptosis, specifically targeting mechanisms within the BCL-2 family of proteins. This pro-apoptotic member, known as a ‘BH3-only’ protein, is crucial in regulating cell death through its interaction with Bcl-2. The r8BID BH3 variant has shown lethal effects on human leukemia cell lines expressing Bcl-2, making it a promising candidate for cancer therapy development. This peptide is fused with Poly-D-arginine to enhance cellular uptake, ensuring effective delivery and action within the target cells.

Key Features

• Pro-apoptotic peptide that effectively targets Bcl-2
• Demonstrated lethality against human leukemia cells
• Enhanced cellular uptake via Poly-D-arginine fusion
• Useful in cancer research and therapeutic applications
• Available in a 0.5 mg quantity

Specifications

FAQ

What is the mechanism of action for Bid BH3-R8?

Bid BH3-R8 induces apoptosis by interacting with Bcl-2 family proteins, promoting cell death in cancerous cells that express Bcl-2. This makes it particularly valuable in cancer research as a potential therapeutic agent.

How is Bid BH3-R8 delivered into cells?

The peptide is fused with Poly-D-arginine, which enhances its ability to permeate cell membranes, allowing it to reach its target effectively and exert its apoptotic effects.

Can Bid BH3-R8 be used in combination with other peptides?

Yes, combining Bid BH3-R8 with other peptides, such as PKG Substrate or Autocamtide-2may enhance the overall effectiveness in your research studies.

Discover the potential of Bid BH3-R8 in your research and therapeutic applications. Buy now to harness the power of this potent peptide for your studies.

Related Products

• CREBtide [KRREILSRRPSYR], 5-FAM labeled

Browse more in Peptides.